Feedback appoints Dr Alastair Riddell to its Board of Directors as incoming Non-Executive Chairman

– UK, Cambridge – Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce the appointment of Dr Alastair Riddell as Non-Executive Chairman with immediate effect. Dr Riddell succeeds Tom Charlton, who becomes Deputy Chairman and who will step down from the board at the conclusion of the AGM which is likely to be held in November 2016.

Dr Riddell, 67, has over 30 years’ experience in the pharmaceutical, life science and biotech industries, with 18 years as a main board director. After 10 years directing phases 1-4 clinical trials of antibiotics, oncology and intensive care products for companies including Lederle and Centocor, he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences; in these roles he was the principal involved in an IPO on UK’s main list, trade sales to international companies in Japan and the USA and significant fund raising rounds. He has been Chairman of Silence Therapeutics and Chairman of Definigen Ltd, a private Cambridge University spinout. He is currently on the Board of three biotechnology companies; AzurRx Biotherapeutics, a private New York based drug development company; Cristal Therapeutics, a Netherlands based company specialising in nanoparticle medicines; and Skyline Vet Pharma, a US based private company repurposing human drugs for use in companion animals. He is also Chairman of the SWAHSN (South West Academic Health Science Network), which seeks to improve and sustain the healthcare provision in the south-west of England by linking innovation from industry, academia and the NHS.

Dr Alastair Riddell commented: “I am very pleased to be joining Feedback as it positions itself for growth in the critical market of diagnostic imaging. Its early product in image software analysis is gaining traction in assisting in the interpretation of cancer deposits in lungs. The technology lends itself to other disease areas and seeks to be a seamless addition to existing image analysis procedures that will provide increased confidence in diagnostic accuracy. I am looking forward to helping the Company develop its infrastructure and resources to maximise its potential.”

Tom Charlton, said: “I recently informed the Board that I wished to devote more time to my other investment activities and I intended to step down from the Board at the time of the AGM later this year. As Deputy Chairman, I will retain responsibility for financial matters including the preparation of the annual report and accounts for the year ended May 2016. Alastair has considerable experience as a biotech entrepreneur and will provide knowledgeable leadership to Feedback as we seek to commercialise TexRAD and grow its revenues. His appointment has my full support as well as that of the Board and I very much look forward to working with him.”

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>

Comments are closed.